Scientific Advisory
Board
Chairman
Eugene Butcher, M.D. - Stanford
W. Michael Gallatin, Ph.D. - Former VP Research, ICOS Pharmaceuticals
Trevor John Hastie, Ph.D. -
Stanford
Leroy Hood, M.D., Ph.D. - Institute for Systems Biology
Louis J. Picker, M.D. -
Oregon Health Sciences University
Kevan Shokat, Ph.D. -
UCSF
Nolan Sigal, MD,
Ph.D. - President, Trellis Bioscience
Vibeke Strand,
M.D. - Stanford
Robert John Tibshirani, Ph.D. -
Stanford
Gregory J. del Zoppo, M.D. - Scripps
Eugene Butcher, M.D.
Eugene C. Butcher, M.D., BioSeek co-founder and Chair of the Scientific Advisory Board. Dr. Butcher is a Professor in the Department of Pathology at Stanford University, and a staff physician at the Veterans Affairs Palo Alto Health Care System. He received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.D. from the Washington University School of Medicine, St. Louis, MO. His work has focused on the cellular and molecular mechanisms of leukocyte trafficking in immunity and inflammation, and on systems level insights into mechanisms of cell-cell recognition and function. He has been elected to the American Association of Physicians and has been awarded the Warner Lambert/Parke Davis Award by the American Association of Pathologists, the AAI-Huang Foundation Meritorious Career Award by the American Association of Immunologists, and an Outstanding Inventor Award from Stanford University. He received the Crafoord Prize from the Swedish Academy of Sciences in 2004 for the scientific discovery of mechanisms of leukocyte trafficking contributing to the treatment of arthritis and inflammatory diseases. He is the author of 300 scientific articles and an inventor on nine US patents. Dr. Butcher was Scientific Co-Founder and Co-Chair of the Scientific Advisory Board of Leukosite, Inc. (now merged with Millennium Pharmaceuticals) and has served on the Scientific Advisory Boards of Millennium, Medimmune, and Thios Pharmaceuticals.
Top of page
W. Michael Gallatin, Ph.D.
W. Michael Gallatin is the former Vice President and Scientific Director of ICOS Corporation. He joined ICOS in 1990 as Director of the Cell Adhesion Program and became a Senior Director, Science, in 1992. He was appointed Vice President, Biological Research in 1993. Prior to joining ICOS, Dr. Gallatin was a faculty member of the Fred Hutchinson Cancer Research Center in Seattle, and an affiliate faculty member of the Department of Microbiology at the University of Washington. He has been actively engaged in research relating to immunobiology and cell adhesion for over
20 years. He received his Ph.D. in immunology from the University of Alberta (Canada) and was a postdoctoral fellow at Stanford University.
Top of page
Trevor John Hastie, Ph.D.
Currently a Professor in the Statistics and Biostatistics Departments at Stanford University, Dr. Hastie was formerly a member of the Statistics and Data Analysis Research Group at AT&T Bell Laboratories. With Dr. Tibshirani, he co-authored the monograph "Generalized Additive Models" (1990), published by Chapman and Hall, and he has written numerous research articles in the area of nonparametric regression and classification, computer intensive data analysis techniques, and statistical computing and graphics. He is Associate Editor (since 1994) of the journal Annals of Statistics and Associate Editor (since 1995) of the Journal of Data Mining and Knowledge Discovery. In 1998, he was elected to become a Fellow of the American Statistical Association.
Top of page
Leroy Hood, M.D., Ph.D.
Dr. Leroy Hood, M.D., Ph.D., President and Director, Institute for Systems Biology. Dr. Hood received his M.D. from the Johns Hopkins Medical School and Ph.D. from the California Institute of Technology. Dr. Hood was formerly the William Gates III Professor of Biomedical Sciences and chair of the Molecular Biotechnology department at the University of Washington School of Medicine. Dr. Hood has been a member of the National Academy of Sciences and the American Academy of Arts and Sciences since 1982. Dr. Hood is the recipient of numerous awards, including the Ricketts Medal from the University of Chicago, the 3M Life Sciences Award, the Louis Pasteur Award for Medical Innovation, and the Lasker Basic Medical Sciences Award. He is the author of more than 500 scientific articles, covering areas including immunology, cancer biology, developmental biology, and genomics. Throughout his career, Dr. Hood and his coworkers have played a major role in developing methods of large-scale DNA mapping and sequencing. Dr. Hood has played a role in founding several biotechnology companies including Amgen, Applied Biosystems, Inc., Darwin Molecular Inc., and Rosetta Inpharmatics, Inc. He currently serves as a member of the scientific advisory boards of Illumina, Inc., Fisher Scientific, Iceland Genomics Corp., Immunex Corp., Orchid BioScience, Inc., People Genetics, Real Time Health, and the McLaughlin Research Institute. Dr. Hood is currently President and Director of the Institute for Systems Biology in Seattle, Washington, a private, nonprofit organization aimed at revolutionizing medicine by creating new tools for diagnosis, treatment and prevention of disease at the molecular level.
Top of page
Louis J. Picker, M.D.
Dr. Louis J. Picker, M.D., Professor, Department of Pathology, Oregon Health Sciences University. Dr. Picker received his M.D. from UCSF in 1982 and did his internship and residency in pathology at Harvard University. Dr. Picker was a postdoctoral fellow and clinical instructor in the Department of Pathology at Stanford University, then became a faculty member of the Pathology Department at the University of Texas Southwestern Medical Center at Dallas where he was Director of the Clinical Cellular Immunology and Flow Cytometry Laboratory and Co-Director of the Division of Hematopathology and Immunology. Dr. Picker is a world-renowned expert in flow cytometric analysis of disease-associated T cell subsets. His work with Becton-Dickinson on novel methods for analysis of T cell function has led to important advances in the understanding of pulmonary and cutaneous disease mechanisms, as well as human responses to infectious disease. Dr. Picker is currently Director of the Pathobiology Division at the Oregon Regional Primate Research Center and Director of the Vaccine Program at the Vaccine and Gene Therapy Institute at Oregon Health Sciences University.
Top of page
Kevan Shokat, Ph.D.
Professor Shokat received his B.A. degree in chemistry from Reed College (Portland, Oregon) in 1986, and Ph.D. from UC Berkeley with Professor Peter Schultz on the design and synthesis of haptens for the generation of catalytic antibodies. He moved on to post-doctoral
studies in 1991 with Professor Christopher Goodnow at Stanford
University studying mechanisms of immune self-tolerance in transgenic mice. From 1994 to 1998, he held Assistant Professor and Associate Professor positions in Chemistry and Molecular Biology at Princeton University. There, he developed novel chemical methods for probing protein kinase signaling cascades using unnatural ATP analogs and uniquely specific protein kinase inhibitors. Dr, Shokat is the scientific co-founder of Cellular Genomics Inc, in New Haven, CT, which is utilizing these methods to carry out protein kinase target based drug discovery in several disease areas. In 1999, he moved to become Associate Professor of Cellular and Molecular Pharmacology at the University of California at San Francisco and Associate Professor of Chemistry at the University of California at Berkeley, where in 2001 he was promoted to Professor. Kevan Shokat was awarded Phi Beta Kappa at Reed College in 1986. He received a Life Sciences Research Foundation post-doctoral fellowship in 1991 and received an NSF Early Career Development Award in 1995. He is a Pew Scholar in the Biomedical Sciences (1997), a Cottrell Scholar (1998), a Searle Scholar (1998), a Glaxo-Wellcome Scholar in Organic Chemistry (1998), and an Alfred P. Sloan Fellow (1999). He is the recipient of the 2001 Young Investigator Award from the Protein Society and the Eli Lilly Award in Biological Chemistry in 2002 from the American Cancer Society.
Top of page
Nolan H. Sigal, M.D., Ph.D.
Dr. Sigal is currently President of Trellis Bioscience, Inc., South San Francisco, CA. In addition to his role as a consultant to the biotechnology, venture capital and pharmaceutical industries, Dr. Sigal has served as Executive Vice President, Research and Development, and Chief Scientific Officer at Cytokinetics, Inc. and as Senior Vice President, Drug Discovery for Pharmacopeia,
Inc. and was one of Pharmacopeia's founding scientists. Prior to joining Pharmacopeia, Dr. Sigal held several scientific and management positions during a 10 year period with Merck & Company Inc, including Executive Director of Immunology Research. Dr. Sigal graduated from Princeton University in 1971 with an A.B. in Chemistry. Following completion of an M.D./Ph.D. program at the University of Pennsylvania and a pediatric residency, Dr. Sigal was on the faculty at the University of Toronto before moving to Merck. Most of Dr. Sigal's research focused on understanding the biochemical events involved in the lymphocyte signal transduction. He is the author of over 100 publications and several patents.
Top of page
Vibeke Strand, M.D.
Dr. Vibeke Strand, M.D., Biopharmaceutical Consultant, Clinical Professor [VCF], Division of Immunology, Stanford University School of Medicine; Co-Chair Medical Advisory Board. Dr. Strand is a biopharmaceutical clinical and regulatory consultant with over 20 years experience in designing clinical development programs. Dr. Strand has expertise in developing regulatory and clinical strategies for new product development in immunology and autoimmune disease applications, and has extensive experience with regulatory IND, NDA and BLA filings. She has participated in the preparation of INDs for over 25 biologic and pharmaceutical agents and has prepared and made advisory panel presentations for 6 NDAs and 4 BLAs. These filings include pharmaceutical compounds, monoclonal antibodies, and recombinant proteins for applications in cardiovascular indications, transplantation, rheumatoid arthritis, diabetes, multiple sclerosis, psoriasis, inflammatory bowel disease, systemic lupus, and cutaneous T cell lymphoma. For example, Dr. Strand was responsible for the phase III US clinical program and successful NDA submission for Arava® (Aventis) in rheumatoid arthritis. Dr. Strand has served on numerous advisory panels including those at Amgen, Boehringer Ingelheim, Cypress Bioscience, GD Searle, Hoechst Marion Roussel, Hoffman La Roche, Novartis, RWJ Pharmaceuticals, Seragen, SmithKline Beecham, Vertex, and Astra-Zeneca. She has organized and participated in numerous meetings on new therapies for autoimmune and rheumatic diseases as well as meetings designed to develop consensus regarding outcome measures in clinical trials of agents for rheumatic diseases.
Top of page
Robert John Tibshirani, Ph.D.
Dr. Tibshirani is a Professor in the Departments of Statistics and Health Research and Policy at Stanford University. The recipient of numerous honors, Dr. Tibshirani was selected to receive the prestigious COPSS award in 1996. Given jointly by the leading statistical societies, the award recognizes outstanding contributions to statistics by a statistician under the age of 40. Having authored many articles on nonparametric regression and classification, Dr. Tibshirani is widely regarded as an expert in the field. He also co-authored, with Bradley Efron, the bestselling Introduction to the Bootstrap in 1993. He is Associate Editor (since 1998) of Annals of Statistics and Associate Editor (since 1995) of Statistical Science.
Top of page
Gregory J. del Zoppo, M.D.
Dr. Gregory J. del Zoppo, M.D., Associate Member, Department of Molecular and Experimental Medicine, The Scripps Institute. Dr. del Zoppo received his M.D. from the University of Washington School of Medicine and has been a member of the Division of Hematology/Medical Oncology at Scripps Clinic and Research Foundation since 1983. Dr. del Zoppo serves on the Executive Committees of the International Stroke Society, the Stroke Council, and the American Heart Association. He has published widely on therapeutic interventions for cerebral stroke and is a frequent editorialist for Stroke and Nature Medicine. Dr. del Zoppo is a respected expert in novel stroke therapeutics. His research in experimental models of focal cerebral ischemia has resulted in improved understanding of the role of mechanisms of vascular inflammation injury in cerebral stroke. Dr. del Zoppo has consulted for a variety of pharmaceutical and biotechnology companies including Amgen, Genentech, Biogen, Burroughs Wellcome, SmithKline Beecham, Abbott Laboratories, Boehringer Ingelheim GmbH, and ICOS Corp. Dr. del Zoppo has participated in numerous clinical trials in acute ischemic stroke. He was organizer, principal investigator, and chairman of the Steering
Committee for TTATTS; organizer, principal investigator and chairman of the Executive/Steering Committee for PROACT; and member of the Safety committees for ECASS and ECASSII, among others.
Top of page
|
